FLT3 and acute myeloid leukemia: For example, tumor cells with mutations in the FLT3 tyrosine kinase domain (FLT3-TKD) were sensitive to the type I FLT3 inhibitors crenolanib, gilteritinib and midostaurin, which bind the FLT3 receptor in the active conformation and are known to be active in AML cells with mutations in the FLT3 internal tandem duplication (FLT3-ITD) and FLT3-TKD.